NCT04138251 (GLYCO-1B) is a Phase 2 clinical trial of Empagliflozin in Glycogen Storage Disease Type I, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

Who is sponsoring NCT04138251?

NCT04138251 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

What drugs are being tested in NCT04138251?

Interventions in NCT04138251: Empagliflozin.

What condition does NCT04138251 study?

NCT04138251 studies Glycogen Storage Disease Type I, Glucose 6 Phosphatase Deficiency.

Is NCT04138251 still recruiting?

NCT04138251 is currently status unknown. Last updated 28 October 2019.

Last reviewed 2019-10-28 · How we verify

NCT04138251: GLYCO-1B

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Status unknown Phase 2 Last updated 28 October 2019

What this trial tests

Phase 2 trial testing Empagliflozin in Glycogen Storage Disease Type I in 5 participants. Status unknown.

Timeline

20 June 2019

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	20 June 2019
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across Belgium

Drugs / interventions tested

Empagliflozin (empagliflozin) — full drug profile →

Conditions studied

Glycogen Storage Disease Type I — all drugs for Glycogen Storage Disease Type I →
Glucose 6 Phosphatase Deficiency — all drugs for Glucose 6 Phosphatase Deficiency →

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain — full company profile →

Who can join

Adults 1 to 18, any sex, with Glycogen Storage Disease Type I or Glucose 6 Phosphatase Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
Boulanger C, Stephenne X, Diederich J, Mounkoro P, et al · · 2022 · cited 33× · PMID 35506446 · DOI 10.1002/jimd.12509
Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care.
Rossi A, Simeoli C, Pivonello R, Salerno M, et al · · 2024 · cited 3× · PMID 38556561 · DOI 10.1007/s11154-024-09880-2
The paradox of autoimmunity and autoinflammation in inherited neutrophil disorders - in search of common patterns.
Krzyzanowski D, Oszer A, Madzio J, Zdunek M, et al · · 2023 · cited 2× · PMID 37350970 · DOI 10.3389/fimmu.2023.1128581
Established and emerging non-cellular therapies in inherited bone marrow failure syndromes.
Janczar S, Urbański B, Ussowicz M, Mlynarski W. · · 2026 · PMID 41859097 · DOI 10.3389/fimmu.2026.1773574

Verify or expand the search:

Other trials of Empagliflozin

Trials testing the same drug.

NCT07060417 — Vascular Effects of SGLT2i in Non-diabetic CKD · Phase 2 · not yet recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting

Other Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials

Trials by the same sponsor.

NCT07464938 — New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest · NA · recruiting
NCT07173036 — Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification Accordin · NA · not yet recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
NCT07588490 — Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments · NA · recruiting
NCT07161219 — Implementation of New Exercise Protocols in Cardiac Rehabilitation. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04138251 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Last refreshed: 28 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04138251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing